Abivax Files Financial Documents with French and U.S. Regulatory Bodies

Abivax SA, a biotechnology firm focused on chronic inflammatory disease treatments, has submitted pivotal financial documents to regulatory authorities in France and the U.S. On March 23, 2026, they filed their Universal Registration Document with France's Autorité des Marchés Financiers (AMF) and their Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC).

The Universal Registration Document details the 2025 annual financial outcomes, along with management and corporate governance reports, plus audits from statutory bodies. Interested parties can access these reports through Abivax's official website, as well as the AMF and SEC portals.

Abivax's emphasis on leveraging natural regulatory mechanisms targets stabilizing immune responses in chronic inflammatory diseases, showcasing their commitment to advancing healthcare solutions.